Arrowhead Pharmaceuticals to Present at Upcoming September Conferences

Home/Newsroom/

Arrowhead Pharmaceuticals to Present...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the

company will make presentations at the following upcoming events.

The 23rd Annual NewsMakers in the Biotech

Industry – New York, September 9, 2016

September 9, 10:00 a.m. EDT – Christopher Anzalone, Ph.D.,

Arrowhead president and CEO will deliver a corporate presentation

7th Non-Coding RNA & RNAi Therapeutics Conference – Boston,

September 14-15, 2016

September 14, 4:30 p.m. EDT – Erik Bush, Ph.D., Arrowhead

director of extrahepatic targeting will deliver an oral presentation

titled, “Targeted delivery strategies using Dynamic PolyconjugateTM

(DPCTM) technology”

2016 International HBV Meeting – Seoul, Korea, September 21-24,

2016

September 24, 8:30 a.m. KST – Zhao Xu, Ph.D., Arrowhead senior

scientist will deliver an oral presentation titled, “Functional

HBsAg-encoding HBV fusion transcripts are produced from integrated HBV

DNA in chronically infected chimpanzees – evidence from single molecule,

real time (SMRT) sequencing”

Copies of presentation materials and webcasts can be accessed on the Events

and Presentations page under the Investors section of the Arrowhead

website after each presentation is delivered.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing. The company’s pipeline includes ARC-520 and ARC-521 for

chronic hepatitis B virus infection, ARC-AAT for liver disease

associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary

angioedema and thromboembolic disorders, ARC-LPA for cardiovascular

disease, and ARC-HIF2 for renal cell carcinoma.

For more information please visit www.arrowheadpharma.com,

or follow us on Twitter @ArrowheadPharma.

To be added to the Company’s email list and receive news directly,

please visit

http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including our ability to finance our operations, the

future success of our scientific studies, our ability to successfully

develop drug candidates, the timing for starting and completing clinical

trials, rapid technological change in our markets, and the enforcement

of our intellectual property rights. Our most recent Annual Report on

Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of

the important risk factors that may affect our business, results of

operations and financial condition. We assume no obligation to update or

revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead

Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investor

Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowheadpharma.com
or
Media:
Russo

Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Pharmaceuticals, Inc.

News Provided by Acquire Media